As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.
News|Videos|December 5, 2025
Modernizing Kidney Stone Treatment: Devices, Data, and Clinical Impact
Author(s)Naeem Bhojani, MD, FRCSC, Karen L. Stern, MD
Fact checked by: Patrick Campbell
Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.
Advertisement
Advertisement
Kidney stones are an increasingly common public health problem, with notable increases observed in women1 and children.2 Myriad treatment options exist, ranging from extracorporeal shock wave lithotripsy to ureteroscopy to percutaneous nephrolithotomy. A challenge for clinicians is removing enough of a patient’s stone burden and residual fragments as possible to avoid repeat procedures.
Related to this article
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.
Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.
Advertisement
Advertisement